BlueMount Capital is pleased to report we are assisting an exciting Melbourne based antibody drug development Company to raise funds and with strategic advice.
Imunexus Ltd is a public unlisted Australian company that develops bispecific antibody based drugs.
The Company promises exceptional growth potential in the disciplines of clinical oncology and immunology. Innovative cancer therapeutics are driving value in the pharmaceutical industry, with many newly marketed engineered antibodies taking the lead in their fields.
Using its proprietary library of over 1010 (ten billion) engineered antibodies; Imunexus has identified several drug candidates that the Company aims to take through the drug development process.
Imunexus’ competitive advantage is that unlike most antibody therapeutic companies, Imunexus’ technology can be taken from concept to the identification of drug candidates within less than six months. This advantage is key to Imunexus’ potential.
Progressing, the Company has identified several drug candidates that possess drug-like characteristics. Of these, IMX101 is the closest to entering human clinical trials.
Targeting cancer, IMX101 was characterised and the Company appointed BlueMount to source the funds to complete formal Preclinical Studies that would enable IMX101 to enter Phase I human clinical trials. In parallel, Imunexus shall also advance its other drug candidates and identify new candidates.
With such a deep pool of investigational drugs, Imunexus is positioned to extract value via both 1) the development of drugs in human clinical trials and 2) license the development of non-core drug candidates to industry parties. BlueMount’s assignment comprises being the corporate advisor and are raising funds now of up to $5 million.
BlueMount Capital has been appointed as Corporate Advisor to PROJECT ENERGISE. The client carbonTRACK has developed advanced and innovative software and hardware which allows users to monitor, manage and optimize their energy usage, maximising savings and even allowing users to trade and arbitrage energy.
With its head office located in Melbourne, carbonTRACK commenced operations in 2015. Since then this award winning technology has been deployed in Australia New Zealand and Africa. Funds are now being raised to expand current operations and to support entry and growth in the U.S.A.
BlueMount Capital will lead the raising of $10m. An Investment Deck and Information Memorandum are now available and further details can be accessed on this website.
BlueMount Capital Appointed as Corporate Advisor and Joint Lead Manager for Integrative Health Care Limited (IHC) ASX IPO
BlueMount Capital is pleased to advise that we have been appointed Corporate Advisor and Joint Lead Manager (with Patersons Securities) for the upcoming IPO of Integrative Health Care Limited (IHC).
BlueMount Capital Sydney has partnered with a leading private non-bank lender with a capital pool of $1.3B for commercial property developers that specialises in loans from $1M to $200M.
In 2017 the lender settled $1.8B in loans and looks set to exceed $2B in the financial year to June 2018. Developments can be both residential or commercial in any state with a preference for capital cities or larger regional centres.
Loans are available for property developers for the following types of projects;
- Bridging finance
- Construction finance
- Commercial Property purchases and refinance
- Residential Property where the funds are used for commercial purposes
- Land Banking for developers
- Development Sites
Rates start from 6.5% plus line & establishment fees.
Initial Documentation Required
- Overview of the project with key metrics summarised
- Valuation if available. An old report will suffice. If a valuation is not available, please provide the address and estimated value.
- Copy of the contract of sale (if acquisition).
- Details (lender and outstanding balance) of any mortgages currently on the property.
- Feasibility study for the project – for a construction loan only
- Level of presales achieved to date. – for a construction loan only
For more information or to make an application contact Ross McDowall in the Sydney office.
“In conjunction with BlueMount Capital’s Melbourne office, I am delighted to announce we have secured more than AUD 39 million in debt funding for a leading Melbourne based manufacturing group.
The funds will be used to finalise the purchase of a new factory as well as providing flexible growth oriented banking facilities. The funding includes a range of facilities such as business loans; equipment, trade and invoice finance as well as an overdraft and credit card facilities.
BlueMount Capital worked closely with the new funder and the client to secure the facilities which include more flexible covenants and guarantee arrangements while providing competitive interest rates on all products offered.”
Dr Mark Rainbird
BlueMount Capital was featured in the recent Australia & New Zealand Business Report 2017 in the South China Morning Post.
You can read the full text of the story on the South China Morning Post’s website or download the Australia & New Zealand Business Report 2017
BlueMount Capital is pleased to announce that the Initial Public Offer for Haixi Pharmaceutical International Holdings Limited has opened for investors.
Key IPO Details
- Substantial increasing profits and assets with high margins
- First Chinese pharmaceutical company to be listed on the ASX
- Long-standing brand recognition with 20 years history
- High dividend payout ratio planned at 50% of NPAT, payable twice a year
- Value investment at a P/E lower than sector average on ASX and HKEX
- Plans to expand into the Australian market and intends to acquire or invest in Australian companies in the pharmaceutical sector
- China is the worlds second largest market for pharmaceuticals
The Prospectus for the offer and a Company Presentation can be obtained via:
Open Date: 21 July 2017
Close Date: 27 October 2017
Minimum Investment A$ 2,000
Fast growing capital markets group BlueMount Capital has welcomed Melbourne-based corporate advisory and investment banking firm Kennedy Needham to the BlueMount Capital Group, establishing a presence in Melbourne to complement its Sydney, Brisbane, Perth and Shanghai offices. As part of the merger, Kennedy Needham will rebrand as BlueMount Capital.
The Chairman of BlueMount Capital Dr Saliba Sassine said: “On behalf of the whole BlueMount Group, I take this opportunity to welcome Kennedy Needham into our Group and we look forward to driving our business nationally and internationally with the Melbourne office.”
Brent Needham, the executive Chairman of Kennedy Needham said “BlueMount Capital’s new combined offering will provide our clients with a stronger national presence and a global reach which Kennedy Needham could not go past.”
Co-Founder of BlueMount Capital, Mr Barry Palte, said the firm was attracted to Kennedy Needham because of its respected team of professionals, established relationships, 30 year successful transaction history and Melbourne base. Furthermore, the expanded network creates a major new player which is unique within Australia.
BlueMount Capital is the exclusive Australian member firm of the International Association of Investment Bankers (IAIB www.iaib.org), an international affiliation of investment banks.
Barry Palte, who is also global co-Chairman of IAIB, said: “The combined Group will be able to draw on a truly national and international network to deliver globally relevant solutions to its clients. With 10 IAIB member firms in North America, Europe, Asia and Australia, and current new member discussions in China, Japan, Korea and Brazil, our exclusive IAIB membership enables BlueMount Capital as a mid-sized national firm to provide agility and capability while offering genuine global reach and service to our clients.
“Melbourne plays an increasingly important role in a number of cross-border transactions we are working on and we needed the right partner to strengthen our leading market position. With this merger, BlueMount Capital will be able to offer Victorian businesses and investors more services, a stronger national presence, a truly global network and the rich experience of more than 40 experienced professionals operating in both Australia and China.”
BlueMount Capital was established in 2010 with Australian offices in Brisbane, Perth and Sydney. The Group has recently advised on transactions worth more than $1 billion. This includes China Dairy Corporation’s $300 million market capitalisation IPO; the sale of PinkBerry, one of the leading frozen yoghurt store chains in the world, together with a US based IAIB member; and the $69 million market capitalisation IPO of Boyuan, the first Chinese property developer to list on the Australian Stock Exchange. BlueMount Capital also advised one of China’s largest groups on its bids for State Super Financial Services and Greenstone Group, both of which had enterprise values in excess of $1billion.
Kennedy Needham is currently undertaking an equity raising of up to $200 million for Dairy Farm Investments. The firm recently acted as lead arranger in the corporate sale of Australian Wholefoods to Patties Foods/Pacific Equity Partners as well as the $35 million corporate sale of Popina Foods to ASX listed Freedom Foods Group.
For more details contact:
Kimberley Ramplin, Statecraft firstname.lastname@example.org
Len McDowall representing BlueMount Capital was privileged to attend the welcome ceremony at the Westin Hotel to welcome Premier Li to Sydney.
Premier Li was welcomed by Australian Prime Minister Turnbull and many senior government ministers.
Australia and China found unprecedented common ground during Chinese Premier Li Keqiang’s visit to Australia this week.
Premier Li and Prime Minister Malcolm Turnbull are statesmen united in opposition to a common foe: trade protectionism. Addressing an economic forum in Sydney, neither mentioned the United States or President Donald Trump by name but the subtext was as clear as the symbolism.
With President Trump pledging to protect US business against foreign competition, Australia is being positioned as a partner in China’s opportunistic campaign to be seen as the new defender of globalisation and free trade champion of the world.
The Prime Minister told a ballroom packed with businesspeople and politicians at the Westin Hotel that “the cooperation between China and Australia showcases to the region and the world our determination to defend trade liberalisation and advocate the benefits of free trade.”
Premier Li, following Mr Turnbull at the podium, matched his rhetoric, then raised it. He said the China-Australia Free Trade Agreement (ChAFTA) would “show to our region and the world that free trade will deliver benefits to all human beings”.
“If China and Australia join hands they will not only bring benefits to the people, but also to the region, to show the world that … with the example of our co-operation, by working together we will move forward and promote greater progress of mankind.”
Mr Turnbull said he had spoken with Premier Li about working together to conclude the Regional Comprehensive Economic Partnership, the rival China-led 16-member initiative excluding the US which has usurped the TPP as the front runner for new free trade deals in the region.
According to Hugh White, professor of strategic studies at the ANU, this is how America’s long era of leadership in Asia comes to an end.
“As a result of Mr Trump’s approach, Australia will drift away from America and move closer to China,” he wrote in The New York Times. “That does not mean we Australians will become Beijing’s ally, but it does mean we will begin tacitly to acquiesce to China’s claims to regional leadership.”
“It is an opportunity for China to rhetorically and symbolically look like it is building closer relations with Australia and the US for the time being is on the outer,” said Merriden Varrall, director of the East Asia program at the Lowy Institute.
China is Australia’s largest trading partner with two way trade in 2015/16 valued at $150 billion. The headline deal of Premier Li’s visit allows unfettered access for Australian beef to the Chinese market which is expected expand exports of chilled beef especially from the current $1 billion worth
The Nelson Resources Limited (the Company, ASX: NES) Board is pleased to advise that Nelson Resources Limited has today appointed CPS Capital Group Pty Ltd (“CPS”) as lead broker to raise $5,000,000 by the issue of 25,000,000 new shares at $0.20 each the offer closing on the 31st March 2017.
The appointment of CPS a highly successful broker in the resources sector as the lead broker will complement the lead Manager Blue Mount Capital.